The effort will evaluate a genomic instability biomarker in clinical trials and develop a testing approach that could allow laboratories internationally to assess DNA repair deficiencies in prostate cancer.
SOPHiA GENETICS and Myriad Genetics have entered a collaboration to advance prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology initiatives with AstraZeneca.
PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients. The partnership aims to evaluate PrGIS within clinical trials and expand access to targeted therapies through potential companion diagnostic solutions.
Myriad developed PrGIS to support HRD as an actionable biomarker in prostate cancer, where the deficiency is emerging as an important prognostic and predictive indicator. Myriad’s MyChoice CDx test, currently available as a companion diagnostic in ovarian cancer, generates the PrGIS score and is being advanced to include prostate cancer as a new indication.
“This collaboration showcases Myriad’s biopharma capabilities to support development of precision oncology treatments,” says Lou Welebob, senior vice president of companion diagnostics at Myriad Genetics, in a release. “PrGIS is designed to provide biopharma partners with a platform that may support patient stratification in clinical trials and help accelerate companion diagnostic development for precision oncology therapies.”
Decentralized Companion Diagnostic Deployment
Under the agreement, SOPHiA GENETICS is developing its solid tumor application for Extended Homologous Recombination Solution into a decentralized companion diagnostic. The system will integrate Myriad’s PrGIS technology to facilitate local laboratory testing across international markets. SOPHiA GENETICS operates a cloud-based platform serving a global network of more than 1,000 institutions across more than 75 countries.
“Precision medicine has a geographic problem because breakthrough therapies developed in major markets often remain inaccessible to patients in the rest of the world,” says Jess Lambe, vice president and managing director of biopharma business development at SOPHiA GENETICS, in a release. “By pairing Myriad’s world-class biomarker innovation with SOPHiA GENETICS’ global network, we are working toward a solution for this. Together, we’re building a new model for companion diagnostic deployment that could help innovative therapies reach the right patients locally, expanding access to care where it matters the most.”
Myriad plans to present research evaluating PrGIS, co-authored with AstraZeneca, at the upcoming European Society for Medical Oncology Congress 2026. The study findings are expected to further characterize the biomarker signature and support its clinical validation, with full data scheduled for release following the congress embargo period.
